2/2
06:00 pm
rcus
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight [Yahoo! Finance]
Low
Report
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight [Yahoo! Finance]
1/26
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Low
Report
Arcus Biosciences Announces New Employment Inducement Grants
1/23
05:06 am
rcus
Arcus Biosciences (NYSE:RCUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Arcus Biosciences (NYSE:RCUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/18
01:00 am
rcus
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at
Wall Street Ze
Low
Report
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at
Wall Street Ze
1/12
05:02 pm
rcus
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
Medium
Report
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
1/10
01:07 am
rcus
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at
Wall Street
Low
Report
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at
Wall Street
1/8
07:09 am
rcus
Arcus Biosciences (NYSE:RCUS) was given a new $20.00 price target on by analysts at Morgan Stanley.
Medium
Report
Arcus Biosciences (NYSE:RCUS) was given a new $20.00 price target on by analysts at Morgan Stanley.
1/7
04:23 pm
rcus
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs [Yahoo! Finance]
Medium
Report
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs [Yahoo! Finance]
1/7
04:05 pm
rcus
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Medium
Report
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
12/18
04:05 pm
rcus
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/17
11:29 am
rcus
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]
Low
Report
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]
12/17
09:08 am
rcus
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]
Low
Report
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]
12/15
08:44 am
rcus
Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/14
11:36 am
rcus
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]
Low
Report
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]
12/14
01:27 am
rcus
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at
Wall Street Ze
Low
Report
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at
Wall Street Ze
12/12
04:08 pm
rcus
Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/12
01:05 pm
rcus
Arcus Biosciences (NYSE:RCUS) was given a new $30.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Arcus Biosciences (NYSE:RCUS) was given a new $30.00 price target on by analysts at Truist Financial Corporation.
12/12
11:55 am
rcus
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at HC Wainwright from $28.00 to $32.00. They now have a "buy" rating on the stock.
Medium
Report
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at HC Wainwright from $28.00 to $32.00. They now have a "buy" rating on the stock.
12/12
09:11 am
rcus
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio [Yahoo! Finance]
Low
Report
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio [Yahoo! Finance]
12/12
08:30 am
rcus
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
High
Report
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
12/9
06:00 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Low
Report
Arcus Biosciences Announces New Employment Inducement Grants
11/28
12:15 pm
rcus
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a "neutral" rating on the stock.
Low
Report
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a "neutral" rating on the stock.
11/18
04:05 pm
rcus
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Low
Report
Arcus Biosciences to Participate in Two Upcoming Investor Conferences